MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common shares, net of...
$23,143K
Proceeds from issuance of
common stock warrants,...
$13,416K
Proceeds from issuance of
common stock warrants,...
$9,504K
Proceeds from issuance of
pre-funded warrants, net of...
-$2,573K
Proceeds from employee
stock purchase plan
$160K
Proceeds from exercise of
options
$122K
Cash provided by
financing activities
$48,918K
Net increase
(decrease) in cash and cash...
$4,186K
Canceled cashflow
$44,732K
Accounts payable and
accrued liabilities
$1,273K
Share-based compensation
expense
$1,250K
Non-cash interest
expense related to debt
$859K
Research and development
tax credits...
-$271K
Other receivables
-$224K
Amortization of debt costs
$109K
Depreciation of property and
equipment
$25K
Net cash provided by
(used in) investing...
-$34,984K
Net cash used in
operating activities
-$9,748K
Canceled cashflow
$4,011K
Acquisition of short-term
investments
$34,982K
Acquisition of property and
equipment
$2K
Net loss
-$11,922K
Prepaid expenses
$1,829K
Operating lease assets and
liabilities
-$8K
Back
Back
Cash Flow
source: myfinsight.com
Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. (MIST)